---
title: Kenvue (KVUE) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/kvue
ticker: KVUE
as_of: 2026-10-17
sector: Consumer Defensive
industry: Household & Personal Products
---
# Kenvue (KVUE)

Kenvue (KVUE) closed at $18.91 on Oct 16, 2026, right at its model value of $18.83 (from a five-year discounted cash flow).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $18.91 (Oct 16, 2026) |
| Model value (from a five-year discounted cash flow) | $18.83 |
| Price vs model | at model value |
| Range of that model | $10.37 – $46.42 |
| Market value | $36.3B |
| P/E (fiscal 2025) | 24.9 |
| Net margin (fiscal 2025) | 9.7% |
| Free cash flow (fiscal 2025) | $1.7B |
| Dividend yield (trailing twelve months) | 5.51% |
| Beta | 0.45 |
| Cost of capital (WACC) | 6.94% |
| Business classification | Dividend Payer (Low/slowing growth (~1% recent), Moderate margins (10% net margin), Strong dividend yield) |

## On the stock lists

| List | Place | Figure | Page |
| --- | ---: | ---: | --- |
| Highest dividend yield | #19 | 5.51% | https://sweetvaluelab.com/lists/highest-dividend-yield |

## Dividends

| Figure | Value |
| --- | ---: |
| Trailing dividend yield | 5.51% |
| Dividends per share, last 12 months | $1.04 |
| Dividends / free cash flow (fiscal 2025) | 91.8% |
| Raised | 2+ years in a row |
| Growth | — |
| Latest payment | $0.21, ex-date Sep 21, 2026, paid Oct 2, 2026 |

| Year of payments | Dividends per share |
| --- | ---: |
| Trailing twelve months (to Sep 21, 2026) | $2.47 |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $18.83 | $10.37 | $46.42 |
| DCF · Perpetuity growth · 10y | cross check | $19.16 | $11.02 | $46.02 |
| DCF · EBITDA exit · 5y | cross check | $23.40 | $16.44 | $31.58 |
| DCF · EBITDA exit · 10y | cross check | $22.94 | $15.58 | $32.74 |
| P/E · peers | cross check | $28.54 | $23.14 | $29.94 |
| P/E · own history | cross check | $22.99 | $20.81 | $29.50 |
| PEG | sanity check | $20.91 | $20.91 | $20.91 |
| EV/EBITDA · peers | cross check | $25.92 | $21.62 | $32.68 |
| EV/Revenue · peers | cross check | $23.31 | $15.59 | $29.91 |
| Earnings power value | cross check | $8.45 | $6.26 | $11.84 |
| Dividend discount | cross check | $27.64 | $18.14 | $45.69 |

## Insider activity (SEC Form 4)

No open-market insider buys or sales filed in the past 90 days.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Oct 2, 2026 | Lawson Carlton | Group President EMEA & LA | Grant / award | 36,597 | $629,468.4 |
| Oct 2, 2026 | Orlando Matthew | General Counsel | Tax withholding | 14,749 | $253,682.8 |
| Oct 2, 2026 | Orlando Matthew | General Counsel | Grant / award | 35,754 | $614,968.8 |
| Oct 2, 2026 | Stevens Meredith | Chief Operations Officer | Grant / award | 35,754 | $614,968.8 |
| Oct 2, 2026 | Stevens Meredith | Chief Operations Officer | Tax withholding | 15,192 | $261,302.4 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Oct 13, 2026 | 8-K | 1.01 Entry into a Material Agreement; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1944048/000095015726001094/form8-k.htm |
| Aug 6, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1944048/000194404826000142/kvue-20260628.htm |
| Aug 6, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1944048/000194404826000141/kvue-20260806.htm |
| May 22, 2026 | 8-K | 5.07 Submission of Matters to a Shareholder Vote | https://www.sec.gov/Archives/edgar/data/1944048/000194404826000102/kvue-20260521.htm |
| May 7, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1944048/000194404826000098/kvue-20260329.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| Yacktman | 2026-06-30 | 8,051,004 | $153.9M |
| Soros | 2026-06-30 | 2,746,636 | $52.5M |
| Bridgewater | 2026-06-30 | 311,241 | $5.9M |
| Lee Ainslie | 2026-06-30 | 173,991 | $3.3M |

5 tracked managers in all.

## About

Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corpo…

---

Source: https://sweetvaluelab.com/stocks/kvue (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.